Clinical Trial Update: Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients [Phase 2]

View source ↗

Summary

Phase 2 trial investigates Everolimus (Certican) for Cytomegalovirus disease in renal transplant patients. The trial status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Disease

Drugs mentioned

• Certican (everolimus)

Snippet

Sponsor: Marcus Saemann | Conditions: Cytomegalovirus Disease | Phase 2 | Status: UNKNOWN